What is Medmo?
Medmo operates at the intersection of patient advocacy and clinical efficiency, providing a specialized platform designed to navigate the fragmented medical imaging market. By mitigating the administrative burden on imaging centers and ordering physicians, the company facilitates improved patient adherence and optimized capacity management. Its market position is defined by its ability to bridge the gap between diagnostic necessity and operational reality, ultimately reducing the friction that often leads to delayed care and increased costs for patients. Through its innovative approach, Medmo is transforming how imaging services are discovered, scheduled, and managed, thereby driving significant value for all stakeholders in the healthcare ecosystem.
How much funding has Medmo raised?
Medmo has raised a total of $38.6M across 3 funding rounds:
Other Financing Round
$9M
Stock/Share Issuance
$14.6M
Series A
$15M
Other Financing Round (2023): $9M with participation from C2 Ventures, Jerusalem Venture Partners, and Lerer Hippeau Ventures
Stock/Share Issuance (2025): $14.6M, investors not publicly disclosed
Series A (2025): $15M supported by Lerer Hippeau Ventures, Origin Ventures, Covera Health, and Toppan Global Venture Partners
Key Investors in Medmo
Lerer Hippeau Ventures
Lerer Hippeau is a venture capital firm focused on investing in innovative startups, particularly in the early stages such as Seed and Pre-Seed rounds. They aim to support founders with great ideas who are willing to tackle challenging problems, fostering long-term success through their expertise as former operators.
Origin Ventures
Origin Ventures is an early-stage venture capital firm that invests in bold founders and innovative companies transforming productivity and automation through artificial intelligence. They provide capital and resources to help companies scale purposefully.
Covera Health
Covera Health is a leading clinical analytics company that pioneers solutions for clients and providers, focusing on reducing the high costs associated with medical misdiagnoses.
What's next for Medmo?
With the successful closure of its Series A round, Medmo is poised to enter a phase of aggressive market penetration and product refinement. The strategic focus will likely shift toward deepening its integration with existing healthcare provider networks and expanding its clinical analytics capabilities. By leveraging the expertise of its diverse investor base, the company is expected to scale its administrative automation tools, further reducing the overhead associated with diagnostic imaging. As Medmo continues to mature, the emphasis will remain on enhancing patient outcomes through data-driven insights and seamless operational workflows, solidifying its role as a transformative force in the digital health landscape.
See full Medmo company page
